HRT Financial’s Axsome Therapeutics AXSM Stock Holding History

HRT Financial’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$514K	Buy	+2,100	New	+$455K	﹤0.01%	2652

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's AXSM Position: Q2 2026 in Review

HRT Financial opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 178,491 shares worth $43.7M. The stake represents 0.08% of the portfolio and ranks #232 among its holdings. This is a return to the name: HRT Financial previously reported a position in AXSM as recently as Q4 2025.

HRT Financial first reported a position in AXSM in Q4 2019 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

HRT Financial held 178,491 shares of Axsome Therapeutics worth $43.7M as of Q2 2026.
Axsome Therapeutics was a new HRT Financial position in Q2 2026.
Axsome Therapeutics made up 0.08% of HRT Financial's portfolio in Q2 2026, its #232 holding.
HRT Financial first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 7 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.